PDF(Pubmed)
Abstract：
Anthracyclic (ANT) drugs are widely used for patients with malignant tumors and can markedly prolong the disease-free survival rate of patients. As its clinical application becomes more common, information regarding serious cardiotoxicity as a result of ANT treatment is becoming understood. However, to the best of our knowledge, delayed-onset cardiotoxicity due to ANT use has not been studied sufficiently. The present report describes a 36-year-old male patient who presented to Guiqian International General Hospital (Guiyang, China) with a complaint of dyspnea in the last 10 days. Substantially elevated B-type natriuretic peptide levels and echocardiography showing enlargement of the entire heart, of the patient suggested that severe heart failure was the cause of his symptoms. However, the cause of this potential heart failure was not apparent until the patient was questioned about his cancer treatment history. Following consultation to evaluate the assessment of end-stage heart failure, currently only anti-heart failure treatment and symptomatic treatment can be provided. The present report describes this case and reviews the existing literature to provide a basis for the diagnosis and treatment of patients with delayed-onset heart failure following ANT treatment.
摘要：
蒽环类（ANT）药物广泛用于恶性肿瘤患者，可以显着延长患者的无病生存率。随着其临床应用越来越普遍,关于因ANT治疗而导致严重心脏毒性的信息正逐渐被人们所了解.然而,据我们所知,由于使用ANT引起的迟发性心脏毒性尚未得到充分研究。本报告描述了一名36岁的男性患者，他向贵谦国际总医院（贵阳，中国）最近10天内有呼吸困难的主诉。显著升高的B型利钠肽水平和超声心动图显示整个心脏增大，该患者认为严重的心力衰竭是他症状的原因。然而,这种潜在心力衰竭的原因并不明显，直到患者被问及他的癌症治疗史。在咨询以评估终末期心力衰竭的评估后，目前只能提供抗心衰治疗和对症治疗。本报告描述了这种情况，并回顾了现有文献，为ANT治疗后迟发性心力衰竭患者的诊断和治疗提供了依据。
